vimarsana.com

Latest Breaking News On - After previous - Page 1 : vimarsana.com

Dermatology Month in Review: April 2024

In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.

Lazertinib Versus Gefitinib as First-line Treatment in EGFR-mutated Advanced NSCLC

1. Progression-free survival was longer in the lazertinib group vs the gefitinib group (20.6 months vs 9.7 months, with HR 0.45), however, OS data were immature. 2. Treatment-related adverse events were similar across both groups, however, lazertinib had higher rates of parasthesia and pruritus but lower levels of ALT elevations and diarrhea. Evidence Rating Level:

New Long-Term Data from the CHRYSALIS Study Show Median

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.